Efficacy of levocarnitine chloride for myocardial fatty acid metabolism in dialysis patients

Efficacy of levocarnitine chloride for myocardial fatty acid metabolism in dialysis patients - levocarnitine chloride and myocardial fatty acid metabolism

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007650

Enrollment

100

Registered

2012-08-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

levocarnitine chloride oral administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.hemodialysis duration is more than 12 months 2.patients who need erythropoiesis stimulating agents (ESA), more than Darbepoetin alfa 15 or epoetin beta 3000 per week 3.patients who gave written informed consent prior to enrollment

Exclusion criteria

Exclusion criteria: 1.patients with a histry of oral levocarnitine chloride including carnitine supplements on the market 2.female patients who are pregnant, nursing or suspected of pregnancy 3.unsuitable patients

Design outcomes

Primary

Measure	Time frame
1.Serum Asymmeteric dimethylarginen (ADMA) 2.Serum Fatty acid bindingprotein (FABP)3,4 and 5	—

Secondary

Measure	Time frame
1.Serum Acyl carnitine and Free carnitine 2.Plasma Brain natriuretic peptide 3.Serum Cardiac Troponin T 4.Echocardiography 5.Electrocardiogram 6.Cardiothoracic ratio in chest X ray photograph 7.Erithropoietic resistance index	—

Countries

Japan

Contacts

Public ContactN Toshima-Minemura

Seseragi Hospital Internal medicine

toshima-n@seseragi-hosp.jp0270-63-6363

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026